优化胸部器官移植中的乙型肝炎病毒血清保护:HepB-CpG(Heplisav-B)疫苗接种程序的作用
本研究回顾性分析了2020年1月至2023年8月在梅奥诊所三个院区完成Heplisav-B疫苗系列的154例成人胸部器官(心脏和肺)移植受者,比较三种接种策略的移植后血清保护率。结果显示移植前完成两剂并达到血清保护者的移植后血清保护率最高(71%),其次为跨移植接种(46%)和移植后接种(36%),p<0.001。多因素分析表明接种策略是移植后缺乏血清保护的独立预测因素。
要点
- 移植前完成两剂Heplisav-B并达到HBsAb≥10 IU/L者移植后血清保护率最高(54/76,71%)。
- 跨移植接种(aOR 2.482)和移植后接种(aOR 4.963)与移植后缺乏血清保护独立相关。
- 作者认为移植前接种Heplisav-B以达到HBsAb≥10 IU/L是维持移植后HBsAb≥10 IU/L的最佳接种程序。
核心结论
- 接种程序显著预测成人胸部器官移植受者的HBV血清保护。
- 作者认为移植前接种Heplisav-B以达到HBsAb≥10 IU/L是维持移植后HBsAb≥10 IU/L的最佳接种程序。
- 需进一步研究以确定该观察结果是否可复制于非胸部器官移植受者或儿科人群。
研究设计与样本
- 回顾性研究,纳入2020年1月至2023年8月在梅奥诊所明尼苏达州、亚利桑那州和佛罗里达州院区的成人胸部器官(心脏和肺)移植受者。
- 共154例完成Heplisav-B疫苗系列的受者,分为策略A(移植前完成2剂且移植前达到血清保护)、策略B(移植前第1剂、移植后第2剂)和策略C(移植后完成2剂)。
- HBV血清保护定义为HBsAb≥10 IU/L。
主要发现
- 移植后血清保护率:策略A为54/76(71%),策略B为18/39(46%),策略C为14/39(36%),p<0.001。
- 多因素logistic回归显示,策略B(aOR 2.482;95%CI 1.085-5.679;p=0.031)和策略C(aOR 4.963;95%CI 2.106-11.697;p<0.001)是移植后缺乏HBV血清保护的独立预测因素。
关键数值与推荐
- HBV血清保护定义为HBsAb≥10 IU/L。
- 策略A:移植前完成2剂Heplisav-B且移植前达到血清保护。
- 策略B:移植前接受第1剂Heplisav-B,移植后接受第2剂。
- 策略C:移植后完成2剂Heplisav-B。
临床怎么用
- 作者认为移植前接种Heplisav-B以达到HBsAb≥10 IU/L是维持移植后HBsAb≥10 IU/L的最佳接种程序。
- 作者建议需进一步研究以确定该观察结果是否可复制于非胸部器官移植受者或儿科人群。
局限性
- 原文未报告局限性。
- 需进一步研究以确定该观察结果是否可复制于非胸部器官移植受者或儿科人群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Heplisav-B, a CpG-adjuvanted recombinant hepatitis B virus (HBV) vaccine, has a higher seroprotection rate and immunogenicity than the conventional HBV vaccine. This study aimed to identify the predictors of HBV seroprotection post-transplantation in thoracic organ transplant recipients who received Heplisav-B. METHODS: We conducted a retrospective study of adult thoracic organ (heart and lung) transplant recipients at Mayo Clinic sites in Minnesota, Arizona, and Florida between January 2020 and August 2023. Patients who completed Heplisav-B series were classified into three strategies: strategy A (completed 2 doses of Heplisav-B pre-transplantation with achieved seroprotection pre-transplantation), strategy B (received first dose of Heplisav-B pre-transplantation and second dose of Heplisav-B post-transplantation), and strategy C (completed 2 doses of Heplisav-B post-transplantation). HBV seroprotection was defined as HBsAb ≥10 IU/L. RESULTS: A total of 154 thoracic organ transplant recipients completed Heplisav-B vaccine series. Post-transplant seroprotection was highest in strategy A, followed by strategy B and strategy C (54/76 [71 %] vs. 18/39 [46 %] vs. 14/39 [36 %]; p < 0.001). Multivariate logistic regression analysis identified two independent factors predicting lack of HBV seroprotection post-transplantation; both were related to Heplisav-B schedule: strategy B (adjusted odds ratio [aOR], 2.482; 95 % confidence interval [CI] 1.085 5.679; p = 0.031), and strategy C (aOR 4.963; 95 % CI 2.106 11.697; p < 0.001). CONCLUSION: The vaccine schedule significantly predicts HBV seroprotection in adult thoracic organ transplant recipients. Our data supports the recommendation that pre-transplantation Heplisav-B to achieve HBsAb ≥10 IU/L is the optimal vaccination schedule to maintain an HBsAb level of ≥10 IU/L post-transplantation. Further studies are needed to determine whether this observation can be replicated in non-thoracic organ transplant recipients or pediatric populations.
引用
- Chiu CY, Sampathkumar P, Brumble LM, et al. Optimizing hepatitis B virus seroprotection in thoracic organ transplantation: The role of HepB-CpG (Heplisav-B) vaccination schedule. Vaccine. 2025. PMID: 39793537. doi:10.1016/j.vaccine.2025.126705
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。